Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on September 15, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). TRUTAKNA met all prespecified endpoints in final ORIGIN 3 efficacy analysis for adults with primary IgA nephropathy.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- TRUTAKNA met all prespecified endpoints in final ORIGIN 3 efficacy analysis for adults with primary IgA nephropathy
- Positive Phase 3 data strengthens TRUTAKNA’s regulatory and commercial prospects in a disease with progression risk
- Updated corporate presentation includes final ORIGIN 3 efficacy results, providing investors additional trial detail
Item 8.01 · Other Events
- ORIGIN 3 met all prespecified endpoints in 428 adults with primary IgAN at risk for progression
- 52-week eGFR decline: 0.1 versus 5.7 mL/min/1.73m², treatment effect 5.6, p<0.0001
- 104-week annualized eGFR slope: -0.6 versus -5.6 mL/min/1.73m²/year, p<0.0001
- Kidney progression events: 11 versus 38, hazard ratio 0.24, representing 76% risk reduction
- No dialysis, transplant, or death with TRUTAKNA versus 8 placebo patients, with safety comparable to placebo
Item EX-99.1 · Exhibit EX-99.1
- ORIGIN 3 met all prespecified endpoints in 428 patients, supporting TRUTAKNA’s potential transition from accelerated to full approval
- eGFR decline through 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/year, a 5.0 treatment effect with p<0.0001
- Composite kidney progression: 11 vs 38 events, hazard ratio 0.24 and 76% risk reduction through 104 weeks
- No dialysis, transplant, or death events with TRUTAKNA versus 8 with placebo through 104 weeks
- Supplemental BLA planned for Q4 2026, while 350+ patient start forms in ten weeks indicate early launch traction
Item EX-99.2 · Exhibit EX-99.2
- ORIGIN 3 final results support Vera’s planned sBLA submission in Q4 2026 and potential full FDA approval in 2027
- TRUTAKNA improved eGFR by 5.6 mL/min/1.73m at 52 weeks versus placebo, supporting kidney-protection claims
- Composite kidney disease progression risk fell 76%, with hazard ratio 0.24 through 104 weeks
- Safety was broadly comparable to placebo, with serious adverse events 7% versus 15% and discontinuations 2% versus 10%
- Cash, equivalents and marketable securities totaled approximately $499M, plus $425M in potential Oxford Facility capital
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.